Crenezumab - Genentech

Drug Profile

Crenezumab - Genentech

Alternative Names: Anti-Abeta; Crenezumab; MABT5102A; R 5490245; RG 7412; RO 5490245

Latest Information Update: 24 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator AC Immune; Universidad de Antioquia
  • Developer AC Immune; Chugai Pharmaceutical; Genentech; Universidad de Antioquia
  • Class Antibodies; Antidementias; Monoclonal antibodies
  • Mechanism of Action Amyloid beta-protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Alzheimer's disease

Most Recent Events

  • 26 Jun 2017 Genentech completes a phase I trial in Alzheimer's disease in USA (NCT02353598)
  • 21 Mar 2017 Roche initiates the phase III CREAD 2 trial in Alzheimer's disease in Spain (BN29553; EudraCT2016-003288-20).
  • 28 Feb 2017 Genentech plans a phase III CREAD2 trial for Alzheimer's disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top